DR info

臨床試験数 : 7 / 薬物数 : 4 - (DrugBank : 3) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 7

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

N-[1-((5-cyanopyridin-2-yl)methyl)-1H-pyrazol-3-yl]-2-[4-(1-(trifluoromethyl)cyclopropyl)phenyl]acetamide
   Neurocrine Biosciences, Inc.
      -   Phase 2   EUCTR2021-006788-11-DK   Canada;Denmark;France;Germany;Spain;Switzerland;United Kingdom;United States;
NBI-827104
   Neurocrine Biosciences
      2021   Phase 2   NCT04625101   Denmark;Spain;Switzerland;United States;
   Neurocrine Biosciences, Inc.
      2021   Phase 2   EUCTR2020-003141-11-ES   Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-003141-11-DK   Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;
      -   Phase 2   EUCTR2021-006788-11-DK   Canada;Denmark;France;Germany;Spain;Switzerland;United Kingdom;United States;
      -   Phase 2   EUCTR2020-003141-11-DE   Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;